Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sangamo Therapeutics stock in Canada | $10.78

Own Sangamo Therapeutics shares in just a few minutes.

Sangamo Therapeutics, Inc
+$0.27 (+2.81%)

Sangamo Therapeutics is a biotechnology business based in the US. Sangamo Therapeutics stocks (SGMO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $12.01 – an increase of 3.36% over the previous week. Sangamo Therapeutics employs 413 staff and has a trailing 12-month revenue of around $131.4 million.

How to buy Sangamo Therapeutics stock in Canada

  1. Choose a platform. If you're a beginner, our stock trading table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: SGMO in this case.
  5. Research Sangamo Therapeutics stocks. The platform should provide the latest information available.
  6. Buy your Sangamo Therapeutics stocks. It's that simple.

How has Coronavirus impacted Sangamo Therapeutics's stock price?

Since the stock market crash in March caused by coronavirus, Sangamo Therapeutics's stock price has had significant positive movement.

Its last market close was $10.78, which is 30.98% up on its pre-crash value of $7.44 and 124.12% up on the lowest point reached during the March crash when the stocks fell as low as $4.81.

If you had bought $1,000 worth of Sangamo Therapeutics stocks at the start of February 2020, those stocks would have been worth $802.76 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,476.75.

Sangamo Therapeutics stock price

Use our graph to track the performance of SGMO stocks over time.

Sangamo Therapeutics stocks at a glance

Information last updated 2021-07-23.
Latest market close$10.78
52-week range$9.14 - $19.43
50-day moving average $11.1244
200-day moving average $12.1917
Wall St. target price$20.89
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.988

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost Feature Table description
Wealthsimple Trade
Stocks, ETFs
Get a $50 bonus when you open a Wealthsimple Trade account and deposit and trade at least $100.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
$9.99 + $1.25 contract ($4.99 + $1.25 contract if completed 150 trades or more a quarter)
$9.99 ($4.99 if completed 150 trades or more a quarter)
Pay no annual account fees.
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
CIBC Investor's Edge
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95 - $6.95
$4.95 - $6.95 (+$1.25 per contract)
$0 if conditions met, otherwise $100/year
$4.95 - $6.95 is applicable for online stock, ETF and option trades only. Pay $4.95 when you qualify as an Active Trader (trade 150+ times per quarter).
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Interactive Brokers
Stocks, Bonds, Options, ETFs, Currencies, Futures
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
Min. $1.00, Max. 0.5% of trade value
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$9.95 + $1 per contract
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$6.95 - $8.75 + $1.25 per contract
$0 if conditions met, otherwise $25/quarter
$0 - $8.75
Trade 100 select ETFs free of charge.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Sangamo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sangamo Therapeutics price performance over time

Historical closes compared with the last close of $10.78

1 month (2021-06-28) -11.28%
3 months (2021-04-28) -12.57%

Sangamo Therapeutics financials

Revenue TTM USD$131.4 million
Gross profit TTM USD$-62,455,000
Return on assets TTM -11.23%
Return on equity TTM -28.73%
Profit margin -94.38%
Book value $3.273
Market capitalisation USD$1.5 billion

TTM: trailing 12 months

How to short and sell Sangamo Therapeutics stocks

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "SGMO.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 11.8 million Sangamo Therapeutics stocks held short by investors – that's known as Sangamo Therapeutics's "short interest". This figure is 13.9% down from 13.7 million last month.

There are a few different ways that this level of interest in shorting Sangamo Therapeutics stocks can be evaluated.

Sangamo Therapeutics's "short interest ratio" (SIR)

Sangamo Therapeutics's "short interest ratio" (SIR) is the quantity of Sangamo Therapeutics stocks currently shorted divided by the average quantity of Sangamo Therapeutics stocks traded daily (recently around 1.1 million). Sangamo Therapeutics's SIR currently stands at 10.65. In other words for every 100,000 Sangamo Therapeutics stocks traded daily on the market, roughly 10650 stocks are currently held short.

However Sangamo Therapeutics's short interest can also be evaluated against the total number of Sangamo Therapeutics stocks, or, against the total number of tradable Sangamo Therapeutics stocks (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sangamo Therapeutics's short interest could be expressed as 0.08% of the outstanding stocks (for every 100,000 Sangamo Therapeutics stocks in existence, roughly 80 stocks are currently held short) or 0.0993% of the tradable stocks (for every 100,000 tradable Sangamo Therapeutics stocks, roughly 99 stocks are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the stock price and a discouraging interest in betting against Sangamo Therapeutics.

Find out more about how you can short Sangamo Therapeutics stock.

Sangamo Therapeutics stock dividends

We're not expecting Sangamo Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying stocks in our guide.

Sangamo Therapeutics stock price volatility

Over the last 12 months, Sangamo Therapeutics's stocks have ranged in value from as little as $9.14 up to $19.43. A popular way to gauge a stock's volatility is its "beta".

SGMO.US volatility(beta: 1.72)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sangamo Therapeutics's is 1.7203. This would suggest that Sangamo Therapeutics's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Sangamo Therapeutics overview

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; BIVV003, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease; ST-400, a cell therapy, which is in Phase I/II Thales clinical trials for the treatment of transfusion dependent beta thalassemia. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, an anti-CD19 CAR-T cell therapy for the treatment of cancer. ST-101 gene therapy for phenylketonuria. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.

Stocks similar to Sangamo Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site